- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Vitality Biopharma Advisor Will Present Pediatric IBD Case Study
Vitality Biopharma announced company advisor Dr. Natasha Ryz will be presenting at an international research symposium in Montréal.
Vitality Biopharma (OTCQB:VBIO) announced company advisor Dr. Natasha Ryz will be presenting at an international research symposium in Montréal.
As quoted in the press release:
Dr. Ryz will provide a poster presentation titled “Cannabinoid Treatment Induces Remission in Drug-Resistant Pediatric Inflammatory Bowel Disease: A Case Report.” The case report provides clinical results describing a 13-year old boy with drug-resistant Crohn’s disease that achieved disease remission after cannabinoid treatment. Dr. Ryz holds a Ph.D. in Experimental Medicine from the University of British Columbia, where she was a Vanier Scholar.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.